Clinical Neuro-Oncology is a field of Medicine devoted to the management of diseases of the nervous system and their related structures which are caused by abnormal cell growth in brain and spinal cord. This field integrates treatment with prevention, diagnosis, rehabilitation, palliative care, epidemiology and research. The clinical management of Neuro-Oncologic disorders relies on a combination of medical, surgical and radiation treatments which are administered according to individual patient and tumour characteristics. Neuro-Oncology also encompasses the psycho-social care of an individual diagnosed with a tumour, and their family. Neuro-Oncologic diagnosis is based on a range of investigations, such as MRI and CT, that are used for diagnosis, staging and to measure treatment response. Surgery is used to remove gross tumour, alleviate pressure, diagnose and stage pathology and in some cases undertake neuro-navigation/stereo tactics biopsies. Medical care of Neuro-Oncologic diseases relies on even newer and advanced chemo and targeted therapy drugs. Radiation therapy is used as adjuvant therapy in certain Neuro-Oncologic scenarios. The science of Neuro-oncology has evolved impressively over the last few years with advances in technology, medical and surgical interventions, and the range of chemotherapy and targeted therapies now available. Rehabilitation is a critical component of Neuro-Oncology as physical, psychological and social deficits can result when neuro-oncologic conditions arise. Physical, occupational and speech therapies, psychological therapies and cognitive rehabilitation are some of the interventions that are tailored to individual patient needs. Finally, palliative care is essential for individuals and their families across all stages of a Neuro-Oncologic disorder.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States